Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-01-23
2007-01-23
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S366000, C424S093200
Reexamination Certificate
active
09986344
ABSTRACT:
An analgesic benefit is realized by continuously supplying a peptide in vivo that activates an opioid receptor or that interferes with the binding of substance P to its receptors. The long-term, continuous provision of such a peptide can be accomplished by (a) transducing myogenic cells with DNA expressing the peptide and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.
REFERENCES:
patent: WO 91/02745 (1991-03-01), None
patent: WO 92/16547 (1992-10-01), None
patent: WO 96/18303 (1996-06-01), None
Deglon et al. Human Gene Therapy 7:2135-2146, 1996.
Law et al. Cell Transplantation 2:485-505, 1993.
Allen and Rankin. Proceedings of the Experimental Biology and Medicine 194:81-86, 1990.
Morris and Herz (Naunyn Schmiedebergs Arch Pharmacol 336:240-243, 1987 (abstract only).
Beutler et al. “Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts,” J. Neurochem. 64(2): 475-481, 1995.
Skuk, D., “Myoblast transplantaion for inherited myopathies: a clinical approach,” Expert Opin. Biol. Ther. 4 (12): 1871-1875, 2004.
Satoh et al., Myotubes can be formed within implanted adipose tissue, Transplant. Proc. 24(6): 3017-3019, 1992.
Takeuchi, T., et al., “Production of a Therapeutic Peptide Enkephalin from a Variety of Non-Endocrine Cell Lines Using a Novel Expression Vector for Fusion Peptides,” Gene Therapy, vol. 2, pp. 689 (1995).
Sandra, A., “Reversal by Insulin of Concanavalin A Inhibition of Myotube Formation and Evidence for Binding Sites,” Endocrinology, vol. 105, No. 2, pp. 391-401 (Aug. 1979).
Wu, et al., “Implantation of AtT-20 or Genetically Modified AIT-20/hENK Cells in Mouse Spinal Cord Induced Antinociception and Opioid Tolerance,” Journal of Neuroscience, vol. 14, No. 8, pp. 4806-4814 (1994).
Motsenbocker Marvin A.
Priebe Scott D.
LandOfFree
Myoblast transfer therapy for relieving pain and for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Myoblast transfer therapy for relieving pain and for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myoblast transfer therapy for relieving pain and for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761358